LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine (MNMD) with an Outperform rating and $32 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNMD:
- 3 Best Stocks to Buy Now, 10/13/2025, According to Top Analysts
- Mind Medicine’s MM120: Promising Phase 3 Trials and Strategic Growth Potential
- Mind Medicine initiated with a Buy at Needham
- Psychedelic: Exclusive talk with ibogaine clinic Beond
- MindMed Study Highlights Urgent Need for Suicide Risk Screening in GAD Patients